3Barthel CR, Rosenkranz B, Leuenberg A, et al. Pulp cap- ping of carious exposures:treatment outcome after 5 and 10 years: a retrospective study[J]. J Endod, 2000,26 (9) : 525-528.
4Qudeimat MA, Barrieshi-Nusair KM, Owais AI. Calcium hydroxide vs mineral trioxide aggregates for partial pul- potomy of permanent molars with deep caries[J]. Eur Arch Paediatr Dent,2007,8(2) :99-104.
5Miyashita H,Worthington HV, Qualtrough A, et al. Pulp management for caries in adults: maintaining pulp vitality[J]. Cochrane Database Syst Rev,2007,18(2)：4484.
6Barrieshi-Nusair KM,Qudeimat MA. A prospective clini- cal study of mineral trioxide aggregate for partial pulpoto- my in cariously exposed permanent teeth[J]. J Endod, 2006,32(8) :731-735.
7Fuks AB. Current concepts in vital primary pulp therapy [J]. Eur J Paediatr Dent,2002,3(3) ..115-120.
8Petrini M, Ferrante M,Ciavarelli L, et al. Prostaglandin E2 to diagnose between reversible and irreversible pulpitis[J] Int J Immunopathol Pharmacol, 2012,25 (1) .- 157-163.
9Waterhouse PJ, Nunn JH, Whitworth JM. Prostaglandin E2 and treatment outcome in pulp therapy of primary molars with carious exposures[J]. Int J Paediatr Dent, 2002,12(2) :116-123.
10Waterhouse PJ, Whitworth JM, Nunn JH. Development of a method to detect and quantify prostaglandin E2 in pulpal blood from cariously exposed, vital primary molar teeth[J]. Int Endod J, 1999,32(5):381-387.
